AAA-614

N/A

Report date: 2025/11/25 15:57:02

NME

Base Information

Drug NameAAA-614

Drug Alias NameAAA-614FAP-2286Lu-FAP-2286

ClassificationSmall molecules > Heterocyclic drugsRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug Conjugates +[4]

Mechanisms of ActionFibroblast activation protein alpha modulators

TargetsProlyl endopeptidase FAP

Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungCarcinoma, Pancreatic Ductal

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesNovartis Ag

China Registration ClassN/A

Develop Information

Active CompaniesNovartis Ag

Inactive CompaniesN/A

Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungCarcinoma, Pancreatic Ductal

Inactive IndicationsN/A

Other Information

ATC CodeN/A